152 related articles for article (PubMed ID: 2908642)
21. [Ex-vivo treatment of a bone marrow graft].
Bieva CJ
Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
[TBL] [Abstract][Full Text] [Related]
22. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
Neville DM
Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
[TBL] [Abstract][Full Text] [Related]
23. Perspectives in the prevention and treatment of acute graft versus host disease.
Herve P
Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225
[No Abstract] [Full Text] [Related]
24. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant.
Henslee-Downey PJ; Parrish RS; MacDonald JS; Romond EH; Marciniak E; Coffey C; Ciocci G; Thompson JS
Transplantation; 1996 Mar; 61(5):738-45. PubMed ID: 8607177
[TBL] [Abstract][Full Text] [Related]
25. Immunohematological aspects of total body irradiation and bone marrow transplantation for the treatment of leukemia.
van Bekkum DW; Hagenbeek A
Radiother Oncol; 1990; 18 Suppl 1():30-6. PubMed ID: 2247647
[TBL] [Abstract][Full Text] [Related]
26. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
Preijers FW
Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
[TBL] [Abstract][Full Text] [Related]
27. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
Ash RC; Casper JT; Chitambar CR; Hansen R; Bunin N; Truitt RL; Lawton C; Murray K; Hunter J; Baxter-Lowe LA
N Engl J Med; 1990 Feb; 322(8):485-94. PubMed ID: 2300120
[TBL] [Abstract][Full Text] [Related]
28. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead.
Prentice HG; Brenner MK; Gottlieb D
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():225-8. PubMed ID: 2653508
[No Abstract] [Full Text] [Related]
29. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo.
Cobbold S; Martin G; Waldmann H
Transplantation; 1986 Sep; 42(3):239-47. PubMed ID: 3529524
[TBL] [Abstract][Full Text] [Related]
31. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
32. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
Sykes M; Bukhari Z; Sachs DH
Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
[TBL] [Abstract][Full Text] [Related]
33. HLA-DP matching in allogeneic bone marrow transplantation.
Pawelec G; Ehninger G; Schmidt H; Rehbein A; Balko I; Wernet P
Transplant Proc; 1987 Feb; 19(1 Pt 3):2741-3. PubMed ID: 3274584
[No Abstract] [Full Text] [Related]
34. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
Vallera DA; Uckun FM
Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
[No Abstract] [Full Text] [Related]
35. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
Champlin R; Giralt S; Przepiorka D; Ho W; Lee K; Gajewski J; Nimer S; Andersson B; Wallerstein R; Ippolito C
Prog Clin Biol Res; 1992; 377():385-94; discussion 395-8. PubMed ID: 1438435
[No Abstract] [Full Text] [Related]
36. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
Sykes M; Abraham VS; Harty MW; Pearson DA
Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
[No Abstract] [Full Text] [Related]
37. Use of a closed system for V alpha beta-positive T cell depletion of marrow for use in partially mismatched related donor (PMRD) transplantation.
Lee C; Brouillette M; Lamb L; Pati A; Brown S; Thompson J; Parrish R; Henslee-Downey PJ; Gee AP
Prog Clin Biol Res; 1994; 389():523-32. PubMed ID: 7700917
[No Abstract] [Full Text] [Related]
38. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
[TBL] [Abstract][Full Text] [Related]
39. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.
Martin PJ; Hansen JA; Torok-Storb B; Moretti L; Press O; Storb R; Thomas ED; Weiden PL; Vitetta ES
Bone Marrow Transplant; 1988 Sep; 3(5):437-44. PubMed ID: 2973360
[TBL] [Abstract][Full Text] [Related]
40. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease.
Filipovich AH; Vallera DA; Youle RJ; Quinones RR; Neville DM; Kersey JH
Lancet; 1984 Mar; 1(8375):469-72. PubMed ID: 6142206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
